Author
Fuyou Liu
Bio: Fuyou Liu is an academic researcher from Central South University. The author has contributed to research in topics: Kidney disease & Cross-sectional study. The author has an hindex of 2, co-authored 3 publications receiving 1308 citations.
Papers
More filters
TL;DR: The prevalence of chronic kidney disease in China was high in north and southwest and southwest regions compared with other regions, and economic development was independently associated with the presence of albuminuria.
1,588 citations
Nanjing University1, Shanghai Jiao Tong University2, Jilin University3, Shandong University4, Zhejiang University5, Sichuan University6, China Medical University (PRC)7, Dalian Medical University8, Fourth Military Medical University9, Zhengzhou University10, Nanjing Medical University11, Central South University12, Vanderbilt University Medical Center13, Toronto General Hospital14
TL;DR: The associations of mesangial hypercellularity and tubular atrophy/interstitial fibrosis with kidney disease outcomes were confirmed, and the inclusion criteria and statistical analysis were similar to the Oxford study.
125 citations
01 Jan 2012
1 citations
Cited by
More filters
TL;DR: Screening and intervention can prevent chronic kidney disease, and where management strategies have been implemented the incidence of end-stage kidney disease has been reduced, but awareness of the disorder remains low in many communities and among many physicians.
3,207 citations
TL;DR: The burden of CKD was much higher than expected for the level of development, whereas the disease burden in western, eastern, and central sub-Saharan Africa, east Asia, south Asia, central and eastern Europe, Australasia, and western Europe was lower than expected.
2,370 citations
TL;DR: CKD has a high global prevalence with a consistent estimated global CKD prevalence of between 11 to 13% with the majority stage 3, and future research should evaluate intervention strategies deliverable at scale to delay the progression of CKD and improve CVD outcomes.
Abstract: © 2016 Hill et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Chronic kidney disease (CKD) is a global health burden with a high economic cost to health systems and is an independent risk factor for cardiovascular disease (CVD). All stages of CKD are associated with increased risks of cardiovascular morbidity, premature mortality, and/or decreased quality of life. CKD is usually asymptomatic until later stages and accurate prevalence data are lacking. Thus we sought to determine the prevalence of CKD globally, by stage, geographical location, gender and age. A systematic review and meta-analysis of observational studies estimating CKD prevalence in general populations was conducted through literature searches in 8 databases. We assessed pooled data using a random effects model. Of 5,842 potential articles, 100 studies of diverse quality were included, comprising 6,908,440 patients. Global mean(95%CI) CKD prevalence of 5 stages 13.4%(11.7-15.1%), and stages 3-5 was 10.6%(9.2-12.2%). Weighting by study quality did not affect prevalence estimates. CKD prevalence by stage was Stage-1 (eGFR>90+ACR>30): 3.5% (2.8-4.2%); Stage-2 (eGFR 60-89+ACR>30): 3.9% (2.7-5.3%); Stage-3 (eGFR 30-59): 7.6% (6.4-8.9%); Stage-4 = (eGFR 29-15): 0.4% (0.3-0.5%); and Stage-5 (eGFR<15): 0.1% (0.1-0.1%). CKD has a high global prevalence with a consistent estimated global CKD prevalence of between 11 to 13% with the majority stage 3. Future research should evaluate intervention strategies deliverable at scale to delay the progression of CKD and improve CVD outcomes.
2,321 citations
TL;DR: Stroke and ischaemic heart disease were the leading causes of death and DALYs at the national level in China in 2017, and China has made substantial progress in reducing the burden of many diseases and disabilities.
1,874 citations
TL;DR: It has now been shown that combining the MEST score with clinical data at biopsy provides the same predictive power as monitoring clinical data for 2 years; this requires further evaluation to assess earlier effective treatment intervention.
660 citations